INTRODUCTION
The control of asymmetric versus symmetric cell division in stem and progenitor cells balances self-renewal and differentiation to mediate tissue homeostasis and repair and involves key proteins that control cell polarity. In the case of excess symmetric division, too many stem-cell-like daughter cells are generated that can lead to tumor initiation and growth. Conversely, excess asymmetric cell division can severely limit the number of cells available for homeostasis and repair (Gó mez-Ló pez et al., 2014; Inaba and Yamashita, 2012) . The Notch pathway has been implicated in controlling stem cell self-renewal in a number of different contexts (Hori et al., 2013) . However, how cell polarity, asymmetric cell division, and the activation of determinants ultimately impinges upon the control of stem cell expansion and maintenance is not fully understood. In this study, we examine the role of an atypical protein kinase C (aPKC), PRKCi, in stem cell self-renewal and, in particular, determine whether PRKCi acts via the Notch pathway.
PKCs are serine-threonine kinases that control many basic cellular processes and are typically classified into three subgroups-conventional, novel, and the aPKCs iota and zeta, which, in contrast to the others, are not activated by diacylglyceride or calcium. The aPKC proteins are best known for being central components of an evolutionarily conserved Par3-Par6-aPKC trimeric complex that controls cell polarity in C. elegans, Drosophila, Xenopus, zebrafish, and mammalian cells (Suzuki and Ohno, 2006) . Before Notch influences stem cell self-renewal, the regulation of cell polarity, asymmetric versus symmetric cell division, and the segregation of cell fate determinants such as NUMB may first be required (Knoblich, 2008) . For example, mutational analysis in Drosophila has demonstrated that the aPKC-containing trimeric complex is required for maintaining polarity and for mediating asymmetric cell division during neurogenesis via activation and segregation of NUMB (Wirtz-Peitz et al., 2008) . NUMB then functions as a cell fate determinant by inhibiting Notch signaling and preventing self-renewal (Wang et al., 2006) . In mammals, the PAR3-PAR6-aPKC complex also can bind and phosphorylate NUMB in epithelial cells and can regulate the unequal distribution of Numb during asymmetric cell division . During mammalian neurogenesis, asymmetric division is also thought to involve the PAR3-PAR6-aPKC complex, NUMB segregation, and NOTCH activation (Bultje et al., 2009) .
Mice deficient in Prkcz are grossly normal, with mild defects in secondary lymphoid organs (Leitges et al., 2001) . In contrast, deficiency of the Prkci isozyme results in early embryonic lethality at embryonic day (E)9.5 (Seidl et al., 2013; Soloff et al., 2004) . A few studies have investigated the conditional inactivation of Prkci; however, no dramatic changes in progenitor generation were detected in hematopoietic stem cells (HSCs) or the brain (Imai et al., 2006; Sengupta et al., 2011) , although one study found evidence of a role for Prkci in controlling asymmetric cell division in the skin (Niessen et al., 2013) . Analysis may be complicated by functional redundancy between the iota and zeta isoforms and/or because further studies perturbing aPKCs in specific cell lineages and/or at specific developmental stages are needed. Therefore, a complete picture for the 
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Nanog Sox2 Here, we investigate the requirement of Prkci in mouse cells using an in vitro system that bypasses early embryonic lethality. Embryonic stem (ES) cells are used to make embryoid bodies (EBs) that develop like the early post-implantation embryo in terms of lineage specification and morphology and can also be maintained in culture long enough to observe advanced stages of cellular differentiation (Desbaillets et al., 2000) . Using this approach, we provide genetic evidence that inactivation of Prkci signaling leads to enhanced generation of pluripotent cells and some types of multipotent stem cells, including cells with primordial germ cell (PGC) characteristics. In addition, we provide evidence that aPKCs ultimately regulate stem cell fate via the Notch pathway.
RESULTS
Prkci
À/À Cultures Have More Pluripotent Cells Even under Differentiation Conditions First, we compared Prkci null EB development to that of Prkci À/À embryos. Consistent with another null allele (Seidl et al., 2013) , both null embryos and EBs fail to properly cavitate (Figures S1A and S1B). The failure to cavitate is unlikely to be due to the inability to form one of the three germ layers, as null EBs express germ-layer-specific genes ( Figure S1E ). A failure of cavitation could alternatively be caused by an accumulation of pluripotent cells. For example, EBs generated from Timeless knockdown cells do not cavitate and contain large numbers of OCT4-expressing cells (O'Reilly et al., 2011) . In addition, EBs generated with Prkcz isoform knockdown cells contain OCT4+ cells under differentiation conditions (Dutta et al., 2011; Rajendran et al., 2013) . Thus, we first evaluated ES colony differentiation by alkaline phosphatase (AP) staining. After 4 days without leukemia inhibitory factor (LIF), Prkci À/À ES cell colonies retained crisp boundaries and strong AP staining. In contrast, Prkci +/À colonies had uneven colony boundaries with diffuse AP staining (Figures S1F-S1F 00 ).
To definitively detect pluripotent cells, day-12 EBs were assayed for OCT4 and E-CADHERIN (E-CAD) protein expression. Prkci +/À EBs had very few OCT4/E-CAD double-positive cells ( Figure 1A) ; however, null EBs contained large clusters of OCT4/E-CAD double-positive cells, concentrated in a peripheral zone (Figure 1A 0 Figure 1C ). We did not find any difference between heterozygous and wild-type cells with respect to the number of OCT4+ or SSEA1+ cells or in their levels of expression for Oct4, Nanog, and Sox2 (Figures S1I, S1I 0 and S1J). However, we did find that Oct4, Nanog, and Sox2 were highly upregulated in OCT4+ null cells ( Figure S1G ). Thus, together, these data indicate that Prkci À/À EBs contain large numbers of pluripotent stem cells, despite being cultured under differentiation conditions.
Functional Pluripotency Tests
If primary EBs have a pluripotent population with the capacity to undergo self-renewal, they can easily form secondary EBs (O'Reilly et al., 2011) . Using this assay, we found that more secondary EBs could be generated from Prkci À/À versus Prkci +/À EBs, especially at days 6, 10, and 16; even when plated at a low density to control for aggregation ( Figure S1H ). To test whether SSEA1+ cells could maintain pluripotency long term, FACS-sorted Prkci À/À SSEA1+ and SSEA1À cells were plated at a low density and maintained under ES cell culture conditions. SSEA1À cells were never able to form identifiable colonies and could not be maintained in culture ( Figure 1D ). SSEA1+ cells, however, formed many distinct colonies after 2 days of culture, and these cells could be maintained for over 27 passages (Figures 1D 0 , 1E 0 , and 1E 00 ). Prkci +/À SSEA1+ cells formed colonies that easily differentiated at the outer edge, even in the presence of LIF ( Figure 1E ). In contrast Prkci À/À SSEA1+ cells maintained distinct round colonies (Figure 1E 0 ). Next, we determined whether null SSEA1+ cells expressed pluripotency and differentiation markers similarly to normal ES cells. Indeed, we found that Oct4, Nanog, and Sox2 were upregulated in both null SSEA1+ EB cells and heterozygous ES cells. In addition, differentiated markers (Fgf5, T, Wnt3, and Afp) and tissue stem/progenitor cell markers (neural: Nestin, Sox1, and NeuroD; cardiac: Nkx2-5 and Isl1; and hematopoietic: Gata1 and Hba-x) were downregulated in both SSEA1+ cells and heterozygous ES cells ( Figure 1F ). SSEA1+ cells likely have a wide range of potential, since EBs generated from these cells expressed markers for all three germ layers ( Figure 1G ). In addition, as expected, EBs made from null SSEA1+ cells were (F) Sorted null cells express stem cell and differentiation markers at similar levels to normal ES cells (versus heterozygous EBs) (three independent experiments).
(G) EBs made from null SSEA1+ sorted cells express germ layer marker genes at the indicated days. Error bars indicate mean ± SEM, three independent experiments. Scale bars, 100 mm in (A, D, and E); 25 mm in (B). See also Figure S1 . ERK1/2 Signaling during EB Development Stem cell self-renewal has been shown to require the activation of the JAK/STAT3 and PI3K/AKT pathways and the inhibition of ERK1/2 and GSK3 pathways (Kunath et al., 2007; Niwa et al., 1998; Sato et al., 2004; Watanabe et al., 2006) . We found that both STAT3 and phosphorylated STAT3 levels were not grossly altered and that the p-STAT3/STAT3 ratio was similar between heterozygous and null ES cells and EBs ( Figures S2A and S2B ). In addition we did not see any difference in AKT, pAKT, or b-CATENIN levels when comparing heterozygous to null ES cells or EBs ( Figures S2A and S2C) . Thus, the effects observed by the loss of Prkci are unlikely to be due to a significant alteration in the JAK/STAT3, PI3K/AKT, or GSK3 pathways. Next, we investigated ERK1/2 expression and activation. Consistent with other studies showing ERK1/2 activation to be downstream of Prkci in some mammalian cell types (Boeckeler et al., 2010; Litherland et al., 2010) , pERK1/2 was markedly inactivated in Prkci null versus heterozygous ES cells. In addition, during differentiation, null EBs displayed strong pERK1/2 inhibition early (until day 6). Later, pERK1/2 was activated strongly, as the EB began differentiating (Figures 2A and 2B ). By immunofluorescence, pERK1/2 was strongly enriched in the columnar epithelium of control EBs, while overall levels were much lower in Prkci À/À EBs ( Figure 2C ). In addition, high OCT4 expression correlated with a marked inactivation of pERK1/2 ( Figure 2C ). Next, we examined Prkci À/À SSEA1+ cells by western blot. We found that SSEA1+ cells isolated from day-12 null EBs had pSTAT3 expression levels similar to whole EBs, while pERK1/2 levels were low ( Figure 2D ). Thus, these experiments indicate that the higher numbers of pluripotent cells in null EBs correlate with a strong inactivation of ERK1/2.
Neural Stem Cell Fate Is Favored in Prkci À/À EBs
It is well known that ERK/MEK inhibition is not sufficient for pluripotent stem cell maintenance (Ying et al., 2008) ; thus, other pathways are likely involved. Therefore, we used a TaqMan Mouse Stem Cell Pluripotency Panel (#4385363) on an OpenArray platform to investigate the mechanism of Prkci action. Day 13 and day 20 Prkci
EBs expressed high levels of pluripotency and stemness markers versus heterozygous EBs, including Oct4, Utf1, Nodal, Xist, Fgf4, Gal, Lefty1, and Lefty2. However, interestingly, EBs also expressed markers for differentiated cell types and tissue stem cells, including Sst, Syp, and Sycp3 (neural-related genes), Isl1 (cardiac progenitor marker), Hba-x, and Cd34 (hematopoietic markers). Based on this first-pass test, we sought to determine whether loss of Prkci might favor the generation of neural, cardiac, and hematopoietic cell types and/or their progenitors. First, we found that null EBs contained many more NESTIN-and PAX6-positive cells than heterozygous EBs ( (B) Quantification of pERK1/2 normalized to non-phosphorylated ERK1/2 (three independent experiments; mean ± SEM; **p < 0.01). (C) pERK1/2 Y202/Y204 is strongly expressed in the columnar epithelium of heterozygous EBs that have just cavitated. Null EBs have lower expression. OCT4 and pERK1/2 expression do not co-localize. Scale bar, 100 mm.
Y202/Y204 levels are lower in null SSEA1+ sorted cells than in heterozygous or in null day-12 EBs that have undergone further differentiation. pSTAT3 and STAT levels are unchanged. See also Figure S2 . and progenitor markers) (Sansom et al., 2009; Tohyama et al., 1992) . In addition, quantification of PAX6 immunofluorescence (easier to quantify because of its nuclear localization) using a pixel count method (Fogel et al., 2012) revealed more abundant PAX6+ cells in null EBs versus heterozygous EBs. This difference was no longer evident at day 16, presumably because most of the new neural progenitors had differentiated ( Figure 3D ). Indeed, differentiated neuronal markers MAP2 and TUJ1 could be expressed in null cell cultures ( Figures 3C and 3C 0 ). Retinoic acid (RA) treatment both in EBs and ES cells promotes neurogenesis (Xu et al., 2012) . We found that, even under RA induction, null cultures contained a larger population of NESTIN+ and a smaller population of TUJ1+ cells when compared to heterozygous cultures (Figures 3E and 3F) . Again, null neural progenitors were capable of undergoing some differentiation, since we could find cells expressing NEUROD, NEUN, and MAP2 (Figures 3F 0 -3F 000 ). We also assessed neurogenesis in monolayer culture, using media that promotes neural stem cell generation supplemented with a low concentration of RA (Xu et al., 2012) . Similar to the EB assay, we found that null ES cells generated a larger NESTIN+ and smaller TUJ1+ population compared to heterozygous ES cells (Figures S3C and S3D) . Like in EBs, MAP2-and TUJ1-positive cells could still be found in the null cultures ( Figure S3D 0 ). Thus, using several different neural-induction assays, we found that the absence of Prkci correlates with the production of more neural progenitors and that, although these cells may favor self-renewal, they are still capable of progressing toward differentiation. (Ericson et al., 1992) ; therefore, we also examined Nkx2-5 expression, a better stem cell marker and regulator of cardiac progenitor determination (Brown et al., 2004) , by RT-PCR and immunofluorescence. In null EBs, Nkx2-5 was upregulated ( Figure 4D ). In addition, in response to RA, which can promote cardiac fates in vitro (Niebruegge et al., 2008) (D) EBs were assessed for PAX6 expression, and the images were used for quantification ( Figures S3A and S3B) . The pixel count ratio of PAX6+ cells in null EBs (green) is substantially higher than that found in heterozygous EBs (black) (three independent experiments; mean ± SEM; *p < 0.05). (E-F 000 ) Day 4 after RA treatment, Prkci
EBs have more NESTIN-than TUJ1-positive neurons (E and F). However, null cells can still terminally differentiate into NEUROD-, NEUN-, and MAP2-positive cells (F 0 -F 000 ). Scale bars, 25 mm in (A and C) and 50 mm in (E). See also Figure S3 . , the pixel count ratio for ISL1 expression indicates that null EBs (green) have larger ISL1 populations than heterozygous EBs (black) (three independent experiments, n = 20 heterozygous EBs, 21 null EBs total; mean ± SEM; *p < 0.05). In (B, B 0 , D, F, and F 0 ), RA treatment induces more NKX2-5 (both nuclear and cytoplasmic) and a-ACTININ expression in null EBs. Arrows point to fibers in (F 0 ). (G) Null EBs (green) generate more beating EBs with RA treatment compared to heterozygous EBs (black) (four independent experiments; mean ± SEM; *p < 0.05, ***p < 0.001). (H) Dissociated null EBs of different stages (green) generate more erythrocytes in a colony-forming assay (CFU-E) (four independent experiments; mean ± SEM; **p < 0.01). (I) Examples of red colonies. (J) Gene expression for primitive HSC markers is upregulated in null EBs (relative to heterozygous EBs) (three independent experiments; mean ± SEM). Scale bars, 50 mm in (A, B, and E); 100 mm in (F), and 25 mm in (I). See also Figure S4 .
null versus heterozygous EBs with RA induction (Figures 4F and 4F 0 ). In addition, many more Prkci À/À EBs were beating after days 6 and 12 of culture ( Figure 4G ). Hba-x expression is restricted to yolk sac blood islands and primitive erythrocyte populations (Lux et al., 2008; Trimborn et al., 1999) . Cd34 is also a primitive HSC marker (Sutherland et al., 1992) . Next, we determined whether the elevated expression of these markers observed with OpenArray might represent higher numbers of primitive hematopoietic progenitors. Using a colony-forming assay (Baum et al., 1992) , we found that red colonies (indicative of erythrocyte differentiation; examples in Figure 4I ) were produced significantly earlier and more readily from cells isolated from null versus heterozygous EBs ( Figure 4H ). By quantitative real-time PCR, upregulation of Hba-x and Cd34 genes confirmed the OpenArray results ( Figure 4J ). In addition, we found Gata1, an erythropoiesis-specific factor, and Epor, an erythropoietin receptor that mediates erythroid cell proliferation and differentiation (Chiba et al., 1991) , to be highly upregulated in null versus heterozygous EBs ( Figure 4J ). These data suggest that the loss of Prkci promotes the generation of primitive erythroid progenitors that can differentiate into erythrocytes.
To determine whether the aforementioned tissue stem cells identified were represented in the OCT4+ population that we described earlier, we examined the expression of PAX6, ISL1, and OCT4 in adjacent EB sections. We found that cells expressing OCT4 appeared to represent a distinct population from those expressing PAX6 and ISL1 (although some cells were PAX6 and ISL1 double-positive) ( Figures S4A-S4C ).
Prkci
À/À Cells Are More Likely to Inherit NUMB/aNOTCH1 Symmetrically The enhanced production of both pluripotent and tissue stem cells suggests that the mechanism underlying the action of Prkci in these different contexts is fundamentally similar. Because the Notch pathway controls stem cell self-renewal in many contexts (Hori et al., 2013) , and because previous studies implicated a connection between PRKCi function and the Notch pathway (Bultje et al., 2009; Smith et al., 2007) , we examined the localization and activation of a key player in the Notch pathway, NUMB, (Inaba and Yamashita, 2012 Figure 5D ). Although individual cells from null EBs that were OCT4+ or PAX6+ more likely to exhibit non-polarized NUMB distribution ( Figures S5A and S5B) , we decided to use an assay that allowed for FACS purification, followed by the more stringent doublet assay. Therefore, we chose CD24 (heat-stable antigen; BA-1), a cell-surface marker that is highly expressed in pre-differentiated neurons and neuroblasts (Pruszak et al., 2009) Because NUMB can be directly phosphorylated by aPKCs (both PRKCi and PRKCz) Zhou et al., 2011) , loss of Prkci might be expected to lead to decreased NUMB phosphorylation. Three NUMB phosphorylation sites-Ser7, Ser276, and Ser295-could be aPKC mediated . By immunofluorescence, we found that one of the most well-characterized sites (Ser276), was strongly inactivated in null versus heterozygous EBs, especially in the core (Figures 5F and 5G ). Western analysis also confirmed that the levels of pNUMB (Ser276) were decreased in null versus heterozygous EBs ( Figure S5F ). Thus, genetic inactivation of Prkci leads to a marked decrease in the phosphorylation status of NUMB.
Notch pathway inhibition by NUMB has been observed in flies and mammals (Berdnik et al., 2002; French et al., 2002) . Therefore, we investigated whether reduced Numb activity in Prkci À/À EBs might lead to enhanced NOTCH1 activity and the upregulation of the downstream transcriptional readouts (Meier-Stiegen et al., 2010 ). An overall increase in NOTCH1 activation was supported by western blot analysis showing that the level of activated NOTCH1 (aNOTCH1) was strongly increased in day 6 and day 10 null versus heterozygous EBs ( Figure S5G ). This was supported by immunofluorescence in EBs, where widespread strong expression of aNOTCH1 was seen in most null cells ( Figures 5I and 5I 0 ), while in heterozygous EBs, this pattern was observed only in the OCT4+ cells ( Figures 5H and 5H  0 ) . (legend continued on next page)
To examine the localization of aNOTCH1 and to better quantify the results seen in Figures 5H and 5I , doublets from dissociated EBs were scored. As seen with NUMB localization, null doublets were more likely to have symmetric localization of aNOTCH1 in comparison to heterozygous doublets ( Figure 5K ; examples in Figures 5M To determine whether Notch pathway activation is required in the absence of Prkci, we examined AP activity and OCT4 expression while blocking the Notch pathway using DAPT to inhibit g-secretase (Sastre et al., 2001 ). DMSO-treated null ES cells stayed undifferentiated (sharp-edged colonies, strong AP staining); however, treatment of null ES cells with 3 mM DAPT led to more differentiation (AP-negative cells with cellular extensions) ( Figures  5N, 5O, and S5J ). In addition, OCT4 is strongly expressed in day-4 control ES cell cultures; however, in the presence of DAPT, OCT4 expression is much decreased both in monolayer culture (Figures 5P-5R ) and in null EBs (48% lower OCT4+ signal versus DMSO controls, pixel counting on EB sections; data not shown). These results support the idea that activated Notch signaling is required in the absence of Prkci to see enhanced pluripotency.
Taken together, the combined effects of decreased NUMB activation, favored symmetric distribution of NUMB and aNOTCH1 and increased NOTCH1 activity support a model whereby loss of Prkci leads to sustained generation of pluripotent and some tissue stem cell populations (Figure 5S ; and see Discussion).
Additional Loss of PRKCz Activity Boosts the Number of OCT4-, SSEA1-, and STELLA-Positive Cells
The generation and maintenance of pluripotent stem cells from new sources or tissue stem cells for basic or translational research can be challenging, and there is need for new in vitro strategies. A PKC inhibitor (Gö6983) that inhibits PKCa, -b, -g, -d, and -z has been used to help maintain mouse and rat ES cells in the absence of LIF (Dutta et al., 2011; Rajendran et al., 2013) . Thus, we hypothesized that treating null cells with Gö6983 might lead to better (D) Doublets from day-10 null EBs have more symmetric inheritance when compared to day-10 heterozygous doublets (three independent experiments; mean ± SEM; **p < 0.01). A red line indicates a ratio of 1 (equal percent symmetric and asymmetric). (E) CD24 high null doublets exhibited more symmetric NUMB inheritance than CD24 high heterozygous doublets (three independent experiments; mean ± SEM; *p < 0.05). A red line indicates where the ratio is 1. (F and G) Decreased pNUMB (Ser276) (P-R) OCT4 is strongly expressed in day-4 DMSO-treated null ES cultures (P). With DAPT (Q,R), OCT4 expression is decreased. (S) Working model: In daughter cells that undergo differentiation, PRKCi can associate with PAR3 and PAR6. NUMB is recruited and directly phosphorylated. The activation of NUMB then leads to an inhibition in NOTCH1 activation and stimulation of a differentiation/maintenance program. In the absence of Prkci, the PAR3/PAR6 complex cannot assemble (although it may do so minimally with Prkcz). NUMB asymmetric localization and phosphorylation is reduced. Low levels of pNUMB are not sufficient to block NOTCH1 activation, and activated NOTCH1 preserves the stem cell self-renewal program. We suggest that PRKCi functions to drive differentiation by pushing the switch from an expansion phase that is symmetric to a differentiation and/or maintenance phase that is predominantly asymmetric. In situations of low or absent PRKCi, we propose that the expansion phase is prolonged. Scale bars, 50 mm in (A, B, F stem cell expansion compared to loss of just Prkci. In our hands, we found that, under differentiation conditions (no LIF), heterozygous ES cells treated with the inhibitor for 4 days still underwent differentiation ( Figure 6A ), while treated null ES cells largely stayed undifferentiated (Figure 6A 0 ; Figure S6A ). Drug treatment of heterozygous EBs boosted the generation of OCT4-expressing cells (Figure 6B ), while treatment of null EBs resulted in an even larger OCT4+ population ( Figure 6B 0 ). NUMB localization was also moderately affected ( Figure S6B) . By cell sorting, we found that drug treatment significantly increased the percentage of OCT4+ cells in both Prkci +/À and Prkci SSEA1 is expressed in BLIMP1-positive PGCs derived from mouse epiblast stem cells (Hayashi and Surani, 2009 ). Also, PGC-like cells can be derived from isolated SSEA1+/OCT4+ EB cells (Geijsen et al., 2004) . Therefore, we speculated that the increase in SSEA1 and OCT4 due to Gö6983 treatment could represent an increase in the generation of PGC-like cells instead of undifferentiated ES cells. Therefore, we examined the expression of STELLA (a PGC marker). As expected, heterozygous EBs contain small clusters of STELLA+ cells similar to EBs made of wild-type cells ( Figure 6E ) (Payer et al., 2006) . The addition of Gö6983 to Prkci +/À EBs induced a modest increase in the number of STELLA+ cells present in the clusters ( Figure 6F ). Without drug treatment, null EBs contained more clusters, and the clusters contained more STELLA+ cells when compared to heterozygous EBs ( Figures 6E and 6G ). Interestingly, when Prkci À/À EBs were treated with Gö6983, the generation of STELLA+ cells was strongly enhanced (Figure 6G versus Figure 6H 
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Prkci +/- (L-P) Treatment with ZIP results in an increase in OCT4+ and STELLA+ cells. ZIP treatment also results in more cells that are VASA+ (three independent experiments); n = 11 for Prkci +/À , and n = 13 for Prkci +/À + ZIP; n = 14 for Prkci À/À , and n = 20 for Prkci À/À + ZIP; eight EBs assayed for both STELLA and VASA expression). Scale bars, 100 mm in (A and A 0 ); 50 mm in (B and B 0 ); and 25 mm in (E, I, and L). See also Figure S6 .
EBs for VASA (a more differentiated PGC marker). We found many cells that were double positive (a little less than half) ( Figure 6K ) but also cells that expressed VASA only and STELLA only ($23 more than VASA only) ( Figures 6I-6K , red/green arrows). Therefore, the combined effect of loss of Prkci and PKC inhibition via Gö6983 treatment leads to the production of STELLA and VASA+ PGC-like cells.
Next, we examined whether the more specific aPKC inhibitor, ZIP, a myristolated aPKC pseudosubstrate with competitive binding to p62, had similar effects (Price and Ghosh, 2013; Tsai et al., 2015; Yao et al., 2013) . We found that both heterozygous and null EBs treated with ZIP contained more OCT4+ cells compared to un-treated EBs (Figures 6L-6O ). In addition, like Gö6983, ZIP treatment resulted in a modest increase in the percentage of SSEA1+ cells found in heterozygous EBs and a strong increase in the percentage of SSEA1+ cells in null EBs ( Figures S6E-S6F 0 ). Furthermore, like Gö6983, both STELLA+ and VASA+ populations were increased with ZIP treatment (Figure 6P ). Thus, both pluripotent and PGC-like cells can be abundantly generated with Gö6983 or ZIP treatment, suggesting that strategies that inhibit both PRKCi and/or PRKCz may be useful to maintain stem cell self-renewal and/or generate abundant PGC-like cells.
DISCUSSION
In this report, we suggest that Prkci controls the balance between stem cell expansion and differentiation/maintenance by regulating the activation of NUMB, NOTCH1, and Hes /Hey downstream effector genes. In the absence of Prkci, the pluripotent cell fate is favored, even without LIF, yet cells still retain a broad capacity to differentiate. In addition, loss of Prkci results in enhanced generation of tissue progenitors such as neural stem cells and cardiomyocyte and erythrocyte progenitors. In contrast to recent findings on Prkcz (Dutta et al., 2011) , loss of Prkci does not appear to influence STAT3, AKT, or GSK3 signaling but results in decreased ERK1/2 activation. We hypothesize that, in the absence of Prkci, although ERK1/2 inhibition may be involved, it is the decreased NUMB phosphorylation and increased NOTCH1 activation that promotes stem and progenitor cell fate. Thus, we conclude that PRKCi, a protein known to be required for cell polarity, also plays an essential role in controlling stem cell fate and generation via regulating NOTCH1 activation.
Notch Activation Drives the Decision to Self-Renew versus Differentiate Notch plays an important role in balancing stem cell selfrenewal and differentiation in a variety of stem cell types and may be one of the key downstream effectors of Prkci signaling. Sustained Notch1 activity in embryonic neural progenitors has been shown to maintain their undifferentiated state (Jadhav et al., 2006) . Similarly, sustained constitutive activation of NOTCH1 stimulates the proliferation of immature cardiomyocytes in the rat myocardium (Collesi et al., 2008) . In HSCs, overexpression of constitutively active NOTCH1 in hematopoietic progenitors and stem cells supports both primitive and definitive HSC selfrenewal (Stier et al., 2002) . Together, these studies suggest that activation and/or sustained Notch signaling can lead to an increase in certain tissue stem cell populations. Thus, a working model for how tissue stem cell populations are favored in the absence of Prkci involves a sequence of events that ultimately leads to Notch activation. Recent studies have shown that aPKCs can be found in a complex with NUMB in both Drosophila and mammalian cells Zhou et al., 2011) ; hence, in our working model ( Figure 5S ), we propose that the localization and phosphorylation of NUMB is highly dependent on the activity of PRKCi. When Prkci is downregulated or absent (as shown here), cell polarity is not promoted, leading to diffuse distribution and decreased phosphorylation of NUMB. Without active NUMB, NOTCH1 activation is enhanced, Hes/Hey genes are upregulated, and stem/progenitor fate generation is favored. To initiate differentiation, polarization could be stochastically determined but could also be dependent on external cues such as the presentation of certain ligands or extracellular matrix (ECM) proteins (Habib et al., 2013) . When PRKCi is active and the cell becomes polarized, a trimeric complex is formed with PRKCi, PAR3, and PAR6. Numb is then recruited and phosphorylated, leading to Notch inactivation, the repression of downstream Hes/Hey genes, and differentiation is favored (see Figure 5S ). Support for this working model comes from studies in Drosophila showing that the aPKC complex is essential for Numb activation and asymmetric localization (Knoblich, 2008; Smith et al., 2007; Wang et al., 2006) . Additional studies on mouse neural progenitors show that regulating Numb localization and Notch activation is critical for maintaining the proper number of stem/progenitor cells in balance with differentiation (Bultje et al., 2009) . Thus, an important function for PRKCi may be to regulate the switch between symmetric expansion of stem/progenitor cells to an asymmetric differentiation/maintenance phase. In situations of low or absent PRKCi, we propose that the expansion phase is favored. Thus, temporarily blocking either, or both, of the aPKC isozymes may be a powerful approach for expanding specific stem/progenitor populations for use in basic research or for therapeutic applications. These studies, together with data presented here, provide genetic evidence that evolutionarily conserved polarity pathways may play a central role in NOTCH1 activation and stem cell self-renewal in mammals. Further genetic studies using Cre transgenes that are specific for progenitors in the neural plate, primitive erythrocytes, cardiomyocytes, and other progenitors to ablate aPKC function will be needed to determine how generally this mechanism is used in diverse tissues.
Although we do not see changes in the activation status of the STAT3, AKT, or GSK3 pathway, loss of Prkci results in an inhibition of ERK1/2 (Figures 2A and 2B ). This result is consistent with the findings that ERK1/2 inhibition is both correlated with and directly increases ES cell selfrenewal (Burdon et al., 1999) . Modulation of ERK1/2 activity by Prkci has been observed in cancer cells and chondrocytes (Litherland et al., 2010; Murray et al., 2011) . Although it is not clear whether a direct interaction exists between Prkci and ERK1/2, Prkcz directly interacts with ERK1/2 in the mouse liver and in hypoxia-exposed cells (Das et al., 2008; Peng et al., 2008) . The Prkcz isozyme is still expressed in Prkci null cells but evidently cannot sufficiently compensate and activate the pathway normally. Furthermore, knocking down Prkcz function in ES cells does not result in ERK1/2 inhibition, suggesting that this isozyme does not impact ERK1/2 signaling in ES cells (Dutta et al., 2011) . Therefore, although PRKCi may interact with ERK1/2 and be directly required for its activation, ERK1/2 inhibition could also be a readout for cells that are more stem-like. Further studies will be needed to address this question.
Utility of Inhibiting aPKC Function
Loss of Prkci resulted in EBs that contained slightly more STELLA+ cells than EBs made from +/À cells. Furthermore, inhibition of both aPKC isozymes by treating Prkci null cells with the PKC inhibitor Gö6983 or the more specific inhibitor, ZIP, strongly promoted the generation of large clusters of STELLA+ and VASA+ cells, suggesting that inhibition of both isozymes is important for PGC progenitor expansion ( Figure 6 ). It is unclear what the mechanism for this might be; however, one possibility is that blocking both aPKCs is necessary to promote NOTCH1 activation in PGCs or in PGC progenitor cells that may ordinarily have strong inhibitions to expansion (Feng et al., 2014) . Regardless of mechanism, the ability to generate PGC-like cells in culture is notoriously challenging, and our results provide a method for future studies on PGC specification and differentiation.
Expansion of stem/progenitor pools may not be desirable in the context of cancer. Prkci has been characterized as a human oncogene, a useful prognostic cancer marker, and a therapeutic target for cancer treatment. Overexpression of Prkci is found in epithelial cancers (Fields and Regala, 2007) , and Prkci inhibitors are being evaluated as candidate cancer therapies (Atwood et al., 2013; Mansfield et al., 2013) . However, because our results show that Prkci inhibition leads to enhanced stem cell production in vitro, Prkci inhibitor treatment as a cancer therapy might lead to unintended consequences (tumor overgrowth), depending on the context and treatment regimen. Thus, extending our findings to human stem and cancer stem cells is needed.
In summary, here, we demonstrate that loss of Prkci leads to the generation of abundant pluripotent cells, even under differentiation conditions. In addition, we show that tissue stem cells such as neural stem cells, primitive erythrocytes, and cardiomyocyte progenitors can also be abundantly produced in the absence of Prkci. These increases in stem cell production correlate with decreased NUMB activation and symmetric NUMB localization and require Notch signaling. Further inhibition of Prkcz may have an additive effect and can enhance the production of PGC-like cells. Thus, Prkci (along with Prkcz) may play key roles in stem cell self-renewal and differentiation by regulating the Notch pathway. Furthermore, inhibition of Prkci and or Prkcz activity with specific small-molecule inhibitors might be a powerful method to boost stem cell production in the context of injury or disease.
EXPERIMENTAL PROCEDURES
Differentiation Assays
All animal procedures were carried out in accordance with approved Animal Care and Use Protocols at the University of Southern California. Prkci À/À embryo and ES cell derivation, EB culture, and confirmation of phenotype by lentiviral transfection methods are described in the Supplemental Experimental Procedures and Figure S1 . To assay neural differentiation, EBs were treated with 10 mM RA (Sigma; R2625-500MG) during days 2-6. To assay cardiomyoctye differentiation, day 6 and day 12 EBs were treated with 100 nM RA for 2 days. For the colony-forming assay, EBs were dissociated into single cells (0.25% collagenase type IV, GIBCO, 17104-019), resuspended in MethoCult GF M3434 (Stem Cell Technologies), and cultured for 2 weeks. For DAPT treatment, ES cells were cultured for 24 hr without LIF, then for 4 days in 3 mM or 10 mM DAPT (Calbiochem, 565784) or carrier (DMSO). Samples were assayed by immunofluoresence or for alkaline phosphatase activity (Millipore, SCR004).
To inhibit aPKCs, ES cells were treated with 5 mM Gö6983 (Sigma), 20 mM of the pseudo-substrate ZIP (Anaspec, 63361 Myr-SIYRRGARRWRKL), or an equivalent amount of carrier (DMSO) and then used to make EBs, which were treated with 5 mM Gö6983 or 20 mM ZIP every other day. ZIP treatment did not affect Prkcz RNA or protein expression levels ( Figures S6G and S6H ).
Immunofluorescence and sorting assays are described in the Supplemental Experimental Procedures.
RNA Expression Semiquantitative
Total RNA (RNeasy Extraction Kit, QIAGEN) was reverse transcribed using M-MuLV Reverse Transcriptase (New England Biolabs, M0253S) with random hexamers (Invitrogen, N8080127). See Table S2 for PCR primer sequences.
RealTime Ready
Total RNA was isolated with the High Pure RNA Isolation Kit (Roche) and reverse transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche). PCR was carried out using the LightCycler 480 Probes Master Mix and a LightCycler 480 RealTime Ready custom plate (Roche). Unless otherwise noted, expression was normalized to the mean expression of four reference genes (beta-actin, Gapdh, B2m, and Eef1a1).
Quantitative Analysis
The unpaired Student's t test in Microsoft Excel was used to evaluate statistical significance. For doublet analysis, data are displayed as a ratio of symmetric versus asymmetric localization, where the value 1 represents both found equally (details in Supplemental Experimental Procedures).
SUPPLEMENTAL INFORMATION
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